| Title |
Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials
|
|---|---|
| Published in |
Breast Cancer Research and Treatment, January 2019
|
| DOI | 10.1007/s10549-019-05133-y |
| Pubmed ID | |
| Authors |
Fausto Petrelli, Antonio Ghidini, Rebecca Pedersini, Mary Cabiddu, Karen Borgonovo, Maria Chiara Parati, Mara Ghilardi, Vito Amoroso, Alfredo Berruti, Sandro Barni |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 125 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 125 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 16 | 13% |
| Researcher | 16 | 13% |
| Student > Bachelor | 11 | 9% |
| Student > Ph. D. Student | 10 | 8% |
| Student > Master | 10 | 8% |
| Other | 21 | 17% |
| Unknown | 41 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 32 | 26% |
| Pharmacology, Toxicology and Pharmaceutical Science | 15 | 12% |
| Biochemistry, Genetics and Molecular Biology | 9 | 7% |
| Agricultural and Biological Sciences | 4 | 3% |
| Economics, Econometrics and Finance | 3 | 2% |
| Other | 12 | 10% |
| Unknown | 50 | 40% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 March 2023.
All research outputs
#6,515,119
of 23,515,785 outputs
Outputs from Breast Cancer Research and Treatment
#1,421
of 4,732 outputs
Outputs of similar age
#135,247
of 440,150 outputs
Outputs of similar age from Breast Cancer Research and Treatment
#17
of 61 outputs
Altmetric has tracked 23,515,785 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 4,732 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one has gotten more attention than average, scoring higher than 69% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 440,150 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.
We're also able to compare this research output to 61 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.